Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by V Square Quantitative Management LLC

V Square Quantitative Management LLC boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 44.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,440 shares of the pharmaceutical company’s stock after buying an additional 1,052 shares during the quarter. V Square Quantitative Management LLC’s holdings in Vertex Pharmaceuticals were worth $1,438,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. University of Texas Texas AM Investment Managment Co. purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth about $25,000. Annapolis Financial Services LLC bought a new stake in shares of Vertex Pharmaceuticals during the first quarter valued at approximately $27,000. Arlington Trust Co LLC raised its stake in shares of Vertex Pharmaceuticals by 97.1% in the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 33 shares in the last quarter. ICA Group Wealth Management LLC bought a new position in Vertex Pharmaceuticals during the fourth quarter worth about $28,000. Finally, Fortitude Family Office LLC acquired a new stake in Vertex Pharmaceuticals in the 4th quarter valued at $30,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Maxim Group lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. JPMorgan Chase & Co. raised their price target on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $440.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, February 20th. UBS Group reduced their price objective on Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. Finally, Canaccord Genuity Group cut shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and lifted their price objective for the stock from $332.00 to $379.00 in a research note on Wednesday, January 24th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $432.18.

Get Our Latest Stock Report on Vertex Pharmaceuticals

Vertex Pharmaceuticals Stock Down 0.9 %

NASDAQ:VRTX traded down $3.87 on Tuesday, hitting $442.00. The stock had a trading volume of 1,106,747 shares, compared to its average volume of 1,214,523. The company has a quick ratio of 3.29, a current ratio of 3.50 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a 52 week low of $320.01 and a 52 week high of $448.40. The business’s fifty day moving average is $410.97 and its 200 day moving average is $405.48. The company has a market cap of $114.06 billion, a PE ratio of 28.68, a P/E/G ratio of 2.13 and a beta of 0.39.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last announced its quarterly earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share for the quarter, beating the consensus estimate of $3.66 by $1.10. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The business had revenue of $2.69 billion for the quarter, compared to analysts’ expectations of $2.58 billion. During the same quarter last year, the firm earned $2.67 EPS. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the transaction, the executive vice president now owns 55,804 shares in the company, valued at approximately $23,755,762.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Recommended Stories

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.